GGT/Alb比值对慢性HBV感染者肝纤维化的无创诊断价值

何峰; 郜玉峰; 王翔; 张照如

doi:10.3969/j.issn.1001-5256.2021.06.019

GGT/Alb比值对慢性HBV感染者肝纤维化的无创诊断价值

DOI: 10.3969/j.issn.1001-5256.2021.06.019

何峰¹,
郜玉峰²,
王翔¹,
张照如^1, ,

1.
安徽医科大学附属巢湖医院感染疾病科，合肥 238000
2.
安徽医科大学第一附属医院感染疾病科，合肥 230022

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明: 何峰负责课题设计，资料分析，撰写论文；何峰、王翔参与收集数据，修改论文；郜玉峰、张照如负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
何峰(1990—)，男，主要从事病毒性肝炎的临床研究

通信作者:
张照如，zhangzhaoru2020@163.com

中图分类号: R512.62; R575.2
计量
- 文章访问数: 570
- HTML全文浏览量: 148
- PDF下载量: 60
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-04
- 录用日期: 2020-12-03
- 出版日期: 2021-06-20

Value of gamma-glutamyl transpeptidase/albumin ratio in the noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis B virus infection

1.
Department of Infectious Diseases, Chaohu Hospital of Anhui Medical University, Hefei 238000, China
2.
Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

摘要

摘要: 目的评价GGT/Alb比值对慢性HBV感染者肝纤维化程度的无创诊断价值。方法回顾分析2018年1月—2020年3月安徽医科大学附属巢湖医院经肝穿刺活检的慢性HBV感染者资料。根据肝穿刺病理检查结果，将322例患者按照肝纤维化程度分为S0~1(183例)、S2(68例)、S3(35例)、S4(36例)。收集患者的血常规、病毒学、血生化等临床指标。正态分布的计量资料多组间比较采用单因素方差分析，非正态分布的计量资料多组间比较采用Kruskal-Wallis H秩和检验; 计数资料采用χ²检验。采用Spearman等级相关分析评估3种无创模型GGT/Alb比值、APRI评分和FIB-4指数与肝纤维化程度的相关性。绘制GGT/Alb比值的受试者工作特征曲线(ROC)评价其诊断价值。结果随着肝纤维化程度的加重，患者的Alb(F=7.351)、HBV DNA(χ²=2.820)和PLT(F=6.182)逐渐降低，而年龄(χ²=3.145)、GGT(χ²=6.149)、GGT/Alb比值(χ²=7.064)、APRI评分(χ²=9.022)和FIB-4指数(χ²=8.254)逐渐升高，差异有统计学意义(P值均＜0.05)。Spearman等级相关性分析得出，GGT/Alb比值与肝纤维化分期呈正相关(r=0.396，P＜0.01)，其相关系数高于APRI评分(r=0.327，P＜0.01)和FIB-4指数(r=0.370，P＜0.01)。ROC曲线结果显示，在显著肝纤维化、严重肝纤维化和肝硬化患者中，GGT/Alb比值的ROC曲线下面积(AUC)(分别为0.680、0.676、0.695)与APRI评分(AUC分别为0.692、0.698、0.728)和FIB-4指数(AUC分别为0.659、0.661、0.684)相当，差异均无统计学意义(P值均＞0.05)。GGT/Alb比值分别以0.435、0.465和0.465为截断值，其用于诊断显著肝纤维化、严重肝纤维化和肝硬化患者的灵敏度分别为69.1%、66.2%和69.0%，特异度分别为65.4%、65.9%和67.0%。结论与APRI评分和FIB-4指数一样，GGT/Alb比值是一种简单、实用的肝纤维化无创诊断模型，可以对慢性HBV感染者肝纤维程度的诊断提供参考价值。
- 乙型肝炎，慢性 /
- 肝硬化 /
- γ-谷氨酰转肽酶 /
- 白蛋白
Abstract: Objective To investigate the value of gamma-glutamyl transpeptidase (GGT)/albumin (Alb) ratio in the noninvasive diagnosis of liver fibrosis degree in patients with chronic hepatitis B virus (HBV) infection. Methods A retrospective analysis was performed for the clinical data of 322 patients with chronic HBV infection who underwent liver biopsy in Chaohu Hospital of Anhui Medical University from January 2018 to March 2020, and according to liver fibrosis degree based on liver biopsy, the 322 patients were divided into S0-S1 group with 183 patients, S2 group with 68 patients, S3 group with 35 patients, and S4 group with 36 patients. The clinical indices of routine blood test, virology, and blood biochemistry were collected. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups; the chi-square test was used for comparison of categorical data. A Spearman rank correlation analysis was used to investigate the correlation of the three noninvasive models GGT/Alb ratio, aspartate aminotransferase-to-platelet ratio index (APRI) score, and fibrosis-4 (FIB-4) index with liver fibrosis degree. A receiver operating characteristic (ROC) curve was plotted for GGT/Alb ratio to evaluate its diagnostic value. Results With the aggravation of liver fibrosis degree, there were gradual reductions in Alb (F=7.351, P < 0.05), HBV DNA (χ²=2.820, P < 0.05), and platelet count (F=6.182, P < 0.05) and gradual increases in age (χ²=3.145, P < 0.05), GGT (χ²=6.149, P < 0.05), GGT/Alb ratio (χ²=7.064, P < 0.05), APRI score (χ²=9.022, P < 0.05), and FIB-4 index (χ²=8.254, P < 0.05). The Spearman rank correlation analysis showed that GGT/Alb ratio was positively correlated with liver fibrosis stage (r=0.396, P < 0.01), with a significantly higher correlation coefficient than APRI score (r=0.327, P < 0.001) and FIB-4 index (r=0.370, P < 0.001). The ROC curve analysis showed that in the patients with significant liver fibrosis, severe liver fibrosis, and liver cirrhosis, GGT/Alb ratio had similar areas under the ROC curve to APRI score and FIB-4 index (0.680/0.676/0.695 vs 0.692/0.698/0.728 and 0.659/0.661/0.684, all P > 0.05). At the optimal cut-off values of 0.435, 0.465, 0.465, respectively, GGT/Alb ratio had sensitivities of 69.1%, 66.2%, and 69.0%, respectively, and specificities of 65.4%, 65.9%, and 67.0%, respectively, in the diagnosis of significant liver fibrosis, severe liver fibrosis, and liver cirrhosis. Conclusion Like APRI score and FIB-4 index, GGT/Alb ratio is a simple and practical noninvasive model for the diagnosis of liver fibrosis and can provide a reference for the diagnosis of liver fibrosis degree in patients with chronic HBV infection.
- Hepatitis B, Chronic /
- Liver Cirrhosis /
- gamma-Glutamyltransferase /
- Albumin

HTML全文

图 1 GGT/Alb比值、APRI评分和FIB-4指数诊断肝纤维化的ROC曲线

注：a, 显著肝纤维化(≥S2)；b, 严重肝纤维化(≥S3)；c, 肝硬化(S4)。

下载: 全尺寸图片幻灯片

表 1 不同肝纤维化分期临床指标的比较

临床指标	S0~1(n=183)	S2(n=68)	S3(n=35)	S4(n=36)	统计值	P值
男/女(例)	123/60	47/21	24/11	26/10	χ²=0.378	0.954
HBeAg(阳性/阴性, 例)	121/62	48/20	23/12	25/11	χ²=0.565	0.904
年龄(岁)	35(27~45)	38(30~47)	40(36~48)	48(41~54)	χ²=3.145	0.025
PLT(10⁹/L)	176.89±48.96	165.86±52.54	157.05±48.11	140.27±53.17	F=6.182	＜0.001
ALT(U/L)	28(23~35)	42(25~60)	40(25~52)	40(25~56)	χ²=5.202	0.002
AST(U/L)	28(23~35)	35(28~43)	36(26~40)	35(27~40)	χ²=6.457	＜0.001
GGT(U/L)	16(11~30)	27(17~40)	28(15~36)	29(16~40)	χ²=6.149	＜0.001
Alb(g/L)	46.65±2.82	45.18±2.96	40.09±2.87	35.00±3.16	F=7.351	＜0.001
HBV DNA(lg IU/ml)	5.03(3.74~5.77)	4.60(3.74~6.09)	4.34(3.53~5.71)	3.78(3.13~5.11)	χ²=2.820	0.039
GGT/Alb	0.34(0.24~0.62)	0.49(0.28~0.73)	0.60(0.33~0.79)	0.71(0.46~0.97)	χ²=7.064	＜0.001
APRI	0.41(0.31~0.55)	0.56(0.42~0.84)	0.61(0.44~0.89)	1.18(0.82~1.67)	χ²=9.022	＜0.001
FIB-4	1.24(0.91~1.79)	1.55(0.94~2.61)	1.72(0.96~2.59)	1.95(1.11~2.64)	χ²=8.254	＜0.001

下载: 导出CSV

表 2 GGT/Alb比值、APRI评分和FIB-4指数对慢性HBV感染者肝纤维化程度的预测价值

指标	显著肝纤维化(n=139)			严重肝纤维化(n=71)			肝硬化(n=36)
指标	GGT/Alb	APRI	FIB-4	GGT/Alb	APRI	FIB-4	GGT/Alb	APRI	FIB-4
截断值	0.435	0.425	1.560	0.465	0.425	1.560	0.465	0.425	1.67
AUC	0.680	0.692	0.659	0.676	0.698	0.661	0.695	0.728	0.684
95% CI	0.621~0.738	0.634~0.750	0.598~0.719	0.605~0.747	0.626~0.770	0.583~0.739	0.607~0.782	0.639~0.817	0.581~0.787
敏感度(%)	69.1	77.7	66.2	66.2	80.3	69.0	69.0	83.3	69.4
特异度(%)	65.4	53.8	65.9	65.9	53.8	65.9	67.0	53.8	70.9
阳性似然比	2.00	1.68	1.94	2.04	1.74	2.03	2.14	1.81	2.38
阴性似然比	0.47	0.41	0.51	0.50	0.37	0.47	0.45	0.31	0.43
约登指数	0.344	0.315	0.321	0.338	0.341	0.349	0.370	0.372	0.403

下载: 导出CSV

参考文献(19)

[1]	LIU XD, WU JL, LIANG J, et al. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients[J]. World J Gastroenterol, 2012, 18(22): 2784-2792. DOI: 10.3748/wjg.v18.i22.2784.
[2]	CUI Y, JIA J. Update on epidemiology of hepatitis B and C in China[J]. J Gastroenterol Hepatol, 2013, 28(Suppl 1): 7-10. DOI: 10.1111/jgh.12220.
[3]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[4]	de LEDINGHEN V, VERGNIOL J, BARTHE C, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus[J]. Aliment Pharm Ther, 2013, 37(10): 979-988. DOI: 10.1111/apt.12307.
[5]	COSKUN BD, ALTINKAYA E, SEVINC E, et al. The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients[J]. Rev Esp Enferm Dig, 2015, 107(12): 740-744. DOI: 10.17235/reed.2015.3851/2015.
[6]	ZHENG SQ, WANG QZ. Current status and prospects of research on noninvasive diagnosis of liver fibrosis[J]. J Clin Hepatol, 2019, 35(1): 197-200. DOI: 10.3969/j.issn.1001- 5256.2019.01.043. 郑少秋, 王启之. 无创肝纤维化诊断研究现状与前景[J]. 临床肝胆病杂志, 2019, 35(1): 197-200. DOI: 10.3969/j.issn.1001- 5256.2019.01.043.
[7]	ZHAO F, ZHAO J, CHEN J, et al. Comparison of diagnostic value of Fibroscan and ARFI on liver fibrosis in patients with chronic hepatitis B[J/CD]. Chin J Liver Dis (Electronic Version), 2019, 11(2): 71-75. DOI: 10.3969/j.issn.1674-7380.2019.02.015. 赵帆, 赵娟, 陈静, 等. Fibroscan和ARFI对慢性乙型肝炎肝纤维化诊断价值比较[J/CD]. 中国肝脏病杂志(电子版), 2019, 11(2): 71-75. DOI: 10.3969/j.issn.1674-7380.2019.02.015.
[8]	LEMOINE M, SHIMAKAWA Y, NAYAGAM S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut, 2016, 65(8): 1369-1376. DOI: 10.1136/gutjnl-2015-309260.
[9]	ZHANG Z, WANG G, KANG K, et al. The diagnostic accuracy and clinical utility of three noninvasive models for predicting liver fibrosis in patients with HBV infection[J]. PLoS One, 2016, 11(4): e0152757. DOI: 10.1371/journal.pone.0152757.
[10]	WANG H, XUE L, YAN R, et al. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT[J]. J Viral Hepat, 2013, 20(4): e3-e10. DOI: 10.1111/jvh.12010.
[11]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn. 1001-5256.2019.12.007 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn. 1001-5256.2019.12.007
[12]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
[13]	JIN CT, GUO LW, LIANG WF. Research progress on non-invasive serum markers for liver fibrosis assessment in patients with chronic hepatitis B[J/CD]. Chin J Exp Clin infect Dis(Electronic Edition), 2018, 12(1): 11-14. DOI: 10.3877/cma.j.issn.1674-1358.2018.01.003. 金彩婷, 郭利伟, 梁伟峰. 慢性乙型病毒性肝炎肝纤维化无创性血清诊断指标研究进展[J/CD]. 中华实验和临床感染病杂志(电子版), 2018, 12(1): 11-14. DOI: 10.3877/cma.j.issn.1674-1358.2018.01.003.
[14]	XU LM, LIU P, SHEN XZ, et al. Guidelines for integrated Chinese and Western medicine diagnosis and treatment of liver fibrosis (2019 edition)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007. 徐列明, 刘平, 沈锡中, 等. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
[15]	MUELLER S, SEITZ HK, RAUSCH V. Non-invasive diagnosis of alcoholic liver disease[J]. World J Gastroenterol, 2014, 20(40): 14626-14641. DOI: 10.3748/wjg.v20.i40.14626.
[16]	SILVA IS, FERRAZ ML, PEREZ RM, et al. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol, 2004, 19(3): 314-318. DOI: 10.1111/j.1440-1746.2003.03256.x.
[17]	EVERHART JE, WRIGHT EC. Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV)[J]. Hepatology, 2013, 57(5): 1725-1733. DOI: 10.1002/hep.26203.
[18]	YANG JG, HE XF, HUANG B, et al. Rule of changes in serum GGT levels and GGT/ALT and AST/ALT ratios in primary hepatic carcinoma patients with different AFP levels[J]. Cancer Biomark, 2018, 21(4): 743-746. DOI: 10.3233/CBM-170088.
[19]	LEE J, KIM MY, KANG SH, et al. The gamma-glutamyl transferase to platelet ratio and the FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic hepatitis B infection[J]. Br J Biomed Sci, 2018, 75(3): 128-132. DOI: 10.1080/09674845.2018.1459147.